BioSpace News Archive

Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a collaboration with BIOS Clinical Trials Coordinating Center (BIOS CTTC) at Johns Hopkins University, to expedite patient enrollment for the National Institutes of Health (NIH) funded Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) study.

Masimo (NASDAQ: MASI) will release fourth quarter and FY 2022 financial results for the period ended December 31, 2022, after the market closes on Tuesday, February 28, 2023.

Cure Alzheimer’s Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, is pleased to announce the appointment of Drs. John S. Lazo and Patrick C. May to its Research Strategy Council.

ViiV Healthcare, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts from the company’s diverse portfolio of industry-leading innovative HIV treatment and prevention options alongside next-generation pipeline advancements at the Conference on Retroviruses and Opportunistic Infections (CROI 2023) being held in Seattle, Washington from 19 – 22 February 2023.

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2023 on Tuesday, February 21, 2023.

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received an exemption under Section 56 of the Controlled Drugs and Substances Act

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD)

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”) has announced a collaboration with the International Neurorehabilitation Institute (INI) (https://inirehab.com/) in Lutherville, Maryland to perform a clinical trial to assess the capacity of its RGC composition to promote eye health.

The Jackson Laboratory has appointed Gina Rodriguez as vice president of advancement. Rodriguez will lead the Laboratory’s advancement team and be responsible for philanthropic efforts in support of JAX’s mission to improve human health.

Select Medical announced a joint venture agreement with AtlantiCare to own and manage operations of a new inpatient rehabilitation hospital and 13 outpatient physical therapy centers throughout the southeastern region of New Jersey.